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Abstract: Monensin A is an important commercially available natural product isolated 
from Streptomyces cinnamonensins that shows antibiotic and anti-parasitic activities. 
This molecule has a signifi cant infl uence in the antibiotic market, but until now 
there are no studies on putative metabolite formations. Bioorganic catalysts applying 
metalloporphyrins and mono-oxygen donors are able to mimic the cytochrome P450 
reactions. This model has been employed for natural product metabolism studies 
affording several new putative metabolites and in vivo experiments confi rming the 
relevance of this procedure. In this work we evaluated the potential of 10,15,20-tetrakis 
(pentafl uorophenyl) porphyrin metal(III) chloride [Fe(TFPP)Cl] catalyst models to 
afford a putative monensin A metabolite. Oxidation agents such as meta-chloroperoxy 
benzoic acid, iodosylbenzene, hydrogen peroxide 30 wt.% and tert-butyl hydroperoxide 
70 wt.%, were used to investigate different reaction conditions, in addition to the analysis 
of the infl uence of the solvent. The quantifi cation of total monensin A conversion and the 
structure of the new hydroxylated putative metabolite were proposed based on electrospray 
ionization tandem mass spectrometry analysis. The porphyrin tested, afforded moderate 
conversions of monensin A in all reaction conditions and the selectivity was found to be 
dependent on the oxidation/medium employed. 
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Introduction
 Monensin A (MonA) (Figure 1) is an important, 
commercially available polyether ionophore drug (isolated 
from Streptomyces cinnamonensins) that shows antibiotic 
and anti-parasitic activity. It is widely used as a coccidiostat 
in avian species and as a growth promoter in cattle (Agtarap 
et al., 1967; Huczyński, 2012). Ionophores show the 
ability to form stable, electrically neutral complexes with 
alkali metal cations and their antibiotic activity is related 
to their ability to transfer ions across the cell membrane 
barrier (Pressman et al., 1967; Lowici & Huczyński 2013; 
Huczyński, 2012). MonA is characterized by a narrow 
safety margin and several accidental poisonings have been 
described in animals (Nebbia et al., 1999). Nebbia and co-
workers (1999) conducted a study with liver microssomes 
to characterize which P450-isoenzyme is involved in the 
biotransformation of the ionophore and also investigated 
how this process may be affected by tiamulin and 
other chemotherapeutic agents know to produce toxic 
interactions with MonA. In this study it was defi ned that 
P450 3A is important for the oxidative metabolism of 
MonA and helps to defi ne toxic interactions. The P450 3A 
subfamily is the major P450 enzyme present in the human 
liver and is involved in the metabolism of approximately 
half of the drugs commercially available. In this respect the 
possibility that humans could ingest residues of MonA from 
foodstuffs of animal origin stimulated the investigation of 
the phase 1 metabolization (Nebbia et al., 1999). Recent 
reports of signifi cant levels of polyether antibiotic residues 
in chicken meat and eggs have lead to concerns about 
antibiotic resistance and other possible health problems 
(Harris et al., 1998; Rosen, 2001). These two separate 
issues have encouraged the development of studies to 
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better understand the mechanism of metabolization. The 
commercial importance of the polyether as a feed additive 
in poultry farming has also driven the search for new 
derivatives (Elliot et al., 1998). 
 The cytochromes P450 (CYP450) enzymes are 
well known for their roles in the oxidative metabolism in 
living organisms and for their involvement in the formation 
of a wide variety of xenobiotic metabolites (Mansuy, 
2007; Montellano, 2004). Several in vitro procedures 
can be use to predict the phase 1 reactions carried out by 
P450 and synthetic metalloporphyrins, in the presence 
of oxygen donors, are able to mimic oxidation and 
oxygenation transformations. Initially, these procedures 
were successfully applied for drug development (Macleod 
et al., 2007; 2008) and recently started to be use as a model 
to understand natural products phase 1 metabolization. 
 These biomimetic procedures showed good 
transformation yields of natural products such as quinones 
(Pires et al., 2011; Niehues et al., 2012), alkaloids (Schaab 
et al., 2010), lignans (De Santis Ferreira et al., 2012) 
and chrologenic acid derivatives (Santos et al., 2005; 
2008), but revealed no effect on flavonoid oxidation or 
oxygenation. Sequential in vitro reactions with CYP450 
enzymes and in vivo analysis confirm the presence of the 
obtained putative metabolites and validate the procedure. 
Taking together these results shows the great versatility 
of metalloporphyrins as biomimetic models to understand 
phase 1 metabolism of natural products. In addition, 
metalloporphyrin catalysts exhibit a few advantages 
over standard in vitro methods (Bernadou & Meunier, 
2004; Lohmann & Karst, 2008), like the production of 
sufficient amounts of the metabolites with good enough 
purity to allow for their structural characterization, as 
well as pharmacological and toxicological testing. This 
drastically reduces the number of live animals needed 
for metabolization investigations (Bernadou & Meunier, 
2004). Taken together, the above facts have stimulated this 
current investigation of the in vitro oxidation of MonA 
in homogeneous medium by various oxidants, catalyzed 
by [Fe(TFPP)Cl] and to compare the products obtained 
furhter in in vivo analysis. The most important assays for 
determination of monensin A which have been published 
use high-performance liquid chromatography. Since the 
ionophores do not possess any significant UV absorbance, 
it is preferable to use techniques which have the highest 
possible specificity, and this generally means some type 
of mass spectrometry (Blanchflower & Kennedy, 1996). 
Applications of tandem mass spectrometry coupled 
with HPLC in the identification and determination of 
drug metabolites are the most promising technique for a 
sensitive detection, positive identification and quantitation 
of metabolites in vitro metabolism studies (Holčapek et al., 
2008).
Materials and Methods
Material
 MonA was purchased from Sigma-Aldrich. 
The porphyrin 5,10,15,20-tetrakis(pentafluorophenyl)
porphyrin, H2TFPP, was acquired from Mid-Century. 
Metal insertion into this free base-porphyrin was 
performed out using the method of Adler et al. (1970). 
Hydrogen peroxide (30% solution in water) was stored 
at 5 °C and titrated periodically for purity assessment. 
Tert-butyl hydroperoxide (t-BuOOH), 70% solution in 
water and meta-chloroperoxy benzoic acid (m-CPBA) was 
acquired from Acros Organics. Iodosylbenzene (PhIO) 
was synthesized by hydrolysis of iodosylbenzenediacetate 
using a procedure adapted from the literature (Saltzman 
et al., 1973). The solid was carefully dried under reduced 
pressure and kept at 5 °C; its purity was periodically 
controlled by iodometric titration (Lucas et al., 1955). 
Solvents such as dichloromethane (CH2Cl2), dichloroethane 
(C2H4Cl2), acetonitrile (MeCN) and methanol (MeOH) 
were HPLC grade. All compounds used in this study were 
commercially available from Aldrich or Sigma and were 
of analytical grade purity unless otherwise stated.
General oxidation procedure
 Initially the reaction conditions were optimized 
by varying the concentration of catalysts and oxidizers. 
All reactions were performed in an Eppendorf flask (2 
mL) under mechanical stirring (Vibrax VXR agitator) at 
25 ˚C. The reactions were performed in an atmosphere of 
air for 24 h. After this time the products were analyzed by 
silica gel analytical TLC using a mixture of CHCl3:MeOH 
(93:7) as eluent. After elution, the plates were revealed 
with solution of vanillin-sulfuric acid (1% vanillin and 1% 
H2SO4 in ethanol) for visualization of the products. In a 
typical experiment of our group (Macleod et al., 2008; Dos 
Santos et al., 2011) the ideal proportions obtained catalyst/
oxidant/substrate molar ratio was 1:20:20 achieved 
by adding 0.3 mM:6 mM:6 mM in the CH2Cl2 reaction 
medium (no product formation in the blank sample). After 
determination of the conditions of the reaction, and its 
proportions to a study conducted by varying the types of 
reaction mediuns (CH2Cl2, C2H4Cl2, MeCN and MeOH), 
the oxidant used (m-CPBA, PhIO, t-BuOOH and H2O2) 
total of sixteen reactions were analyzed by HPLC-ESI-
MS. Control reactions were carried out in the absence of 
catalyst under the same conditions as the catalytic runs and 
no products were detected.
HPLC-ESI-MS analysis
 The analysis of products formed in oxidation 
reactions was developed by liquid chromatography 
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coupled to mass spectrometry with ESI ionization using 
Varian chromatograph LC-MS 1200L triple quadrupole, in 
the positive ion mode with a capillary voltage of 3.2 kV, 
a cone voltage of 40 V, source temperature 40 ˚C and N2 
dessolvation temperature of 250 ˚C, monitored from m/z 
610 to 800. Table 1 shows the conditions employed in the 
chromatographic analyses. The conversion of MonA was 
quantified by comparison of the retention time and unit 
mass, based on a calibration curve from 10 to 100 μg/mL.
Table 1. Chromatographic conditions used to quantify the yield 
of conversion of monensin in the biomimetic reactions.
Chromatographic conditions
Analytical Column Xterra MS-C18, 150 mm x 2.1mm, 5μm
Solvent A Water (0.1% formic acid)
Solvent B MeOH (0.1% formic acid)
Flow rate 0.3 mL/min
Mobile phase gradient Time %A %B
0:00 30 70
20:00 2 98
21:00 30 70
30:00 30 70
Injection volume 10 μL
Sample concentration 50 μg/mL
Product elucidation by tandem mass spectrometry
 The fragmentation studies were made in 
accordance with previous analyses by this group (Lopes et 
al. 2001; 2002a, b). The low resolution MS/MS spectrum 
of the metabolite product (m/z 709) was obtained using a 
Waters Quattro-LC triple quadrupole mass spectrometer, 
with Z-spray ESI source operating in the positive ion mode. 
The samples were directly introduced into the spectrometer 
through an infusion pump (Harvard Apparatus Holliston 
MA 01746) at a flow rate of 10 μL/min. The capillary 
temperature and voltage were maintained at 250 ˚C and 3 
kV, respectively and the cone energie was 25kV. Nitrogen 
was used for spraying and drying, and argon was used as 
the collision gas. MS/MS analysis of the precursor ion was 
performed with collision energies in 20-70 eV range. 
 Accurate-mass analyses were performed on 
an Apex IV (7 Tesla) Fourier-transform ion cyclotron 
resonance instrument (Bruker Daltonics, Coventry UK). 
Solutions were infused from a Cole-Parmer syringe 
pump into the Apollo ESI source at 120 μL/h. The source 
temperature was 200 ˚C and the source potential was 4.6 
kV. Fragmentation was performed on the isolated precursor 
ions by sustained off-resonance irradiation (SORI) CID 
using CO2 collision gas. The SORI-CID parameters were 
tuned to fragment all of the precursor ions to maximize 
product ion generation. Accurate-masses were obtained 
by a post-acquisition application of a calibration based on 
the MS/MS analysis of Erythromyicn A obtained with the 
same cell pressure and SORI-CID conditions.
Results and Discussion
Oxidation reactions
 Metabolism studies of MonA have been 
performed using several species (steers, rats, calves 
and chickens). The results show that this drug is 
biotransformed extensively to a large number of 
metabolites that are qualitatively similar (Donoho et al., 
1978; Kiel et al., 1998). Some metabolites have been 
tentatively identified previously (for example from 
steers, rats, calves and chickens) which appear to be 
the result of an O-demethylation and/or hydroxylation 
at various positions along the carbon backbone of the 
ionophore molecule (Figure 1) (Davison 1984; Donoho 
et al., 1978; Kiel et al., 1998).
Figure 1. Monensin A and the main metabolites found in in vivo 
systems.
 In this study, the oxidation of MonA was 
performed in the presence of the [Fe(TFPP)Cl], 
which is a commercially available second generation 
metalloporphyrin well established in the literature as 
a good catalyst for drug oxidation (Macleod et al., 
2007; 2008; Faria et al., 2008; Da Silva et al., 2011). 
The reactions were carried out in different media as 
the solubility of the different metabolite products was 
unknown. The substrate conversion was determined 
by a calibration curve (Y=0.2176X+4.535, where X= 
concentration and Y=peak area, r=0.993). Table 2 
shows the effect of different solvents and oxidants on 
MonA oxidation catalyzed by [Fe(TFPP)Cl]. The best 
conditions for conversion/oxidation of MonA achieved 
was 63% conversion using the following system PhIO/
MeCN.
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 The drug metabolites were more soluble in 
either dichloromethane or dichloroethane, and high 
catalytic activity was obtained to Reaction 10, 6 and 
1 as show Table 3. The efficiency of the catalyst in 
methanol was lower compared to acetonitrile and 
chlorinated solvents, this fact can be explained by 
the alcohol acting as a substrate, thus competing with 
MonA for the catalytic species, leading to the formation 
on unwanted by-products (Macleod et al., 2008). In 
other solvents, which do not compete with MonA, the 
catalyst was able to oxidize the drug with yields as high 
as 63%. Such high yields are due to the higher ability 
of MeCN to stabilize the intermediate catalytic species 
since this solvent has a high donor number (DN=14.1) 
this system was also the most efficient in several others 
reports (Bahramian et al., 2006; Macleod et al., 2007; 
2008). Another factor that influences the yields of 
the reactions is the viscosity of the solvent used. The 
highest yields when comparing C2H4Cl2 with CH2Cl2 
is due to higher viscosities. Viscous solvents favour 
“in cage” over “out of cage” of MonA with porphyrin 
(Smith et al., 2006). 
 PhIO was the first oxidant to be used as an oxygen 
donor in this study because it is considered a standard and 
simple oxidant that contains only one oxygen atom and 
is well-adapted for the selective and clean formation of 
metal-oxo intermediates (Groves et al., 1997; Mansuy, 
2007; Bahramian et al., 2006). The initial step in the 
mechanism involves the abstraction of a hydrogen atom 
from the substrate by this intermediate to form a caged 
substrate radical and FeIV hydroxide complex. This step 
is followed by recombination of the hydroxy fragment 
with the substrate radical thus generating a hydroxylated 
metabolite, corresponding to the oxygen rebound model 
(Mansuy, 2007; Bahramian et al., 2006). The oxidation 
of the substrate led to the preferential formation of 
the hydroxylated product at m/z 709. M-CPBA, H2O2 
and t-BOOH were also employed. These oxidants can 
undergo heterolytic cleavage upon coordination to the 
metalloporphyrin central metal ion, which gives rise to 
the active species: oxoferryl porphyrin π-cation radical, 
FeIV(O)P•+ or FeV(O)P. Homolytic cleavage of the O-O 
bond may also occur leading to formation of a less reactive 
intermediate, Me (OH) IVP, as well as the formation of 
Table 3. The effect of different solvents and oxidants on products obtained in biomimetic reactions of monensin A.
Table 2. Total conversion of monensin A (%) by different oxidants and in different media catalyzed by Fe(TFPP) analyzed by LC-
ESI-MS.
Reaction % Reaction % Reaction % Reaction %
m-CPBA 1 57 5 36 9 39 13 23
PhIO 2 49 6 61 10 63 14 15
H2O2 3 36 7 18 11 19 15 2
t-BUOOH 4 44 8 44 12 18 16 21
Media CH2Cl2 C2H4Cl2 MeCN MeOH
*Control reaction in the absence of Fe(TFPP), 0% conversion.
Biomimeticreaction Reaction medium Oxidants
m/z
679 695 709 707
1
CH2Cl2
m-CPBA X - X -
2 PhIO - - X -
3 H2O2 - - X X
4 t-BUOOH X X - X
5
C2H4Cl2
m-CPBA X - X -
6 PhIO - - X -
7 H2O2 - - X X
8 t-BUOOH X X - X
9
MeCN
m-CPBA - X X X
10 PhIO - - X -
11 H2O2 - X - X
12 t-BUOOH - X - X
13
MeOH
m-CPBA - X - X
14 PhIO - - - -
15 H2O2 - - - -
16 t-BUOOH - X - X
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RO• radicals, thus favoring the occurrence of radical 
mechanisms (Dos Santos et al., 2011; Meunier & Bernadou 
2000; Meunier et al., 2004). The catalytic activity seems to 
be highly dependent on the nature of the oxidant - PhIO 
was the most efficient, followed by m-CPBA. Reactions 
using H2O2 afforded the lowest yields, which can be 
explained by the catalyzed dismute process of this oxidant 
in the presence of iron-porphyrin. Moreover, hydrogen 
peroxide was chosen because it is considered to be a clean 
oxidant (water is the only side-product produced) and the 
high yield was obtained in reaction 3 using CH2Cl2 as the 
solvent. 
 Table 3 shows the formation of hydroxylated 
(m/z 709), epoxydized (m/z 707), O-demethylated (m/z 
679) and O-demethylated/hydroxylated compounds 
(m/z 695) as products from the biomimetic oxidation of 
MonA. 
Fragmentation studies of hydroxylated product (m/z 709)
 A previous systematic investigation carried 
out of MonA by ESI-MS showed that it is possible to 
detect [M+H]+ only at low pH and high cone voltage 
(Lopes et al., 2002a,b). The addition of an excess of 
crown ethers to the solution was shown to increase 
the relative intensity of this molecular ion through 
competition of the crown ether for the sodium cation 
(Lopes et al., 2002a,b). This study revealed some 
limitations in employing the protonated precursor ion 
in tandem mass spectrometric studies and revealed the 
importance understanding the fragmentations pathways 
of the sodiated sodium salts as observed for others 
ionophors (Lopes 2002c, Fonseca et al., 2004 ). Lopes 
et al., (2002a,b) found that extensive fragmentation 
of the sodium salts was possible either by increasing 
the energy of the CID process. The full fragmentation 
mechanism of MonA sodium salt was proposed and this 
analysis demonstrated that the common fragmentation 
ions were produced via a Grob-Wharton type mechanism 
(Grob & Baumann, 1955; Grob, 1969; Lopes et al., 
2002a,b; Wharton & Hiegel 1965). The Grob-Wharton 
fragmentations occurred at two different sites in 
the molecule generating two major fragments that 
produced the remaining ions through either pericyclic 
rearrangements or by simple neutral losses. The same 
fragmentation mechanisms occur for the hydroxylated 
product. In the low resolution ESI-MS/MS spectrum 
of the hydroxylated product, the structural fragments 
are possibly resulting in significant fragmentation due 
to Grob-Wharton type mechanisms and/or elimination 
of H2O, as previously proposed by Lopes et al., (2002 
a,b). The molecular formula of the hydroxylated ion were 
obtained by high-resolution accurate-mass MS/MS and 
the results with errors are shown in Table 4.
 Scheme 1 shows the proposed fragmentation of 
the hydroxylated product (m/z 709; ion A). In this scheme, 
we have proposal that the site of protonation is the acid 
function, in accordance with all published data on the 
three-dimensional structure of MonA in the solid state 
(Duax et al., 1980; Martinek et al., 2000; Paz et al., 2003). 
The mechanism is initiated by the neutral elimination of 
mass 186 via a Grob-Wharton fragmentation involving 
ring A (O-4) (Grob & Baumann, 1955; Grob, 1969; Lopes 
et al., 2002a, b; Wharton & Hiegel 1965) resulting in the 
formation of product ion B (m/z 523). Fragment B loses CO 
and H2O, resulting in ions C and D (m/z 495 and m/z 477), 
which have high intensity in the product ion spectra.
Table 4. Molecular formula, observed and calculated masses, 
mass error (ppm) and fragment scheme identify for all the 
fragment ions observed in the accurate-mass ESI-MS/MS 
spectrum of the metabolite m/z 709.
Formula Observed mass Calculated mass Error Identify
C36H62O12Na
+ Not observed 709.4139 - m/z 709
C36H60O11Na
+ 691.4022 691.4033 -1.59 I
C36H58O10Na
+ 673.3927 673.3928 -1.48 J
C36H56O9Na
+ 655.3829 655.3822 +1.06 L
C31H52O8Na
+ Not observed 575.3560 - M
C31H50O7Na
+ 557.3439 557.3454 -2.69 N
C26H44O9Na
+ Not observed 523.2883 - B
C28H46O7Na
+ 517.3142 517.3141 +1.93 P
C28H40O6Na
+ 499.3026 499.3036 -2.00 Q
C25H42O7Na
+ 459.2717 459.2723 -1.30 E
C26H42O4Na
+ 441.2727 441.2716 +2.49 R
C20H32O3Na
+ 343.2268 343.2249 +1.90 G
C17H28O3Na
+ 303.1938 303.1936 +6.59 H
Scheme 1. The proposed fragmentation route showing the formation of product ion m/z 459 in the positive ion ESI-MS/MS of the 
hydroxylated metabolite of monensin A.
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Scheme 2. The proposed fragmentation route showing the formation of product ion m/z 303 in the positive ion ESI-MS/MS of the 
hydroxylated metabolite of monensin A - a crucial ion for the location of the site of hydroxylation.
Scheme 3. The proposed fragmentation route showing the formation of product ion m/z 655.
 The formation of product ions m/z 343 and m/z 
303 (Scheme 2) from product ion E can occur in two 
different mechanistic pathways. Step one, involves the loss 
of H2O of the tetrahydrofuran ring, forming the product ion 
M (m/z 441) which can give rise to the product ion H (m/z 
303) by a Grob-Wharton type fragmentation, followed by 
a neutral loss of mass 40 (assumed to be the elimination of 
1,4 propyne in a charge remote mechanism). In the second 
step, the product ion m/z 303 is formed by loss of mass 156 
from E via a pericyclic rearrangement analogous to the 
elimination of propyne from dihydropyran affording ion 
G’ which lose the side chain given m/z 303. The analysis 
in this study, combined with our previous fragmentation 
studies of monensin A, led us to propose the structure of 
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the hydroxylated metabolite shown in schemes 1 and 2.
 The second proposed fragmentation pathway 
of m/z 709 (Scheme 3) is initiated by the loss of water 
involving oxygen O-11 to produce product ion I (m/z 
691). Ion I can then undergo a pericyclic rearrangement 
analogous to that in the dihydropyran fragment, to produce 
product ion M m/z 575 or the neutral loss of water involving 
oxygens O-10 and O-11 to form product ion L m/z 655. 
The route shown is believed to be the most likely due to 
the formation of the conjugated π-system and because the 
pericyclic rearrangement leading to a loss of mass 116 is 
not observed as shown in Scheme 3.
  The relationship of the hydroxy group (O-5) and 
the ether oxygen (O-4) in ion A, induces a loss of water, to 
produce intermediate ion O (m/z 691) resulting in a third 
possible route for the fragmentation of m/z 709 - shown in 
scheme 4. Ion O can fragment to give product ion P m/z 
517 via the loss of mass 174.
 The fragmentation mechanism proposed in 
scheme 4 suggests the possibility of a water elimination 
from the dihydropyran system of product ion P (m/z 
517) resulting in product ion Q which inturn can go on 
to fragment by a proton migration in the position α to 
the carbonyl, to form product ion R (m/z 441) by loss of 
mass 58. The existence of product ion R (m/z 441) may 
prove to be highly significant as it is the product ion that is 
crucial for determining the position of hydroxylation in the 
precursor ion – the MonA metabolite.
 In conclusion, these results have demonstrated 
the ability of the [Fe(TFPP)Cl] iron porphyrins to mimic 
the action of CYP P450 in monensin A oxidation, with 
the formation of a main products. The formation of these 
products is highly dependent on the oxidant and reaction 
medium. Our studies have also demonstrated the potential 
application of these biomimetic methods as an alternative 
model in the synthesis/search of new drug derivatives of 
antibiotics. This should provide samples sufficient for 
biological tests, as well as aid studies that pursue the 
elucidation of in vivo drug metabolism. In the study, a 
hydroxylated metabolite of MonA was elucidated by high-
resolution accurate-mass tandem mass spectrometry. We 
also have presented a complete fragmentation pathway 
for the hydroxylated derivative of monensin and the 
formulae of all fragments have been proved by accurate-
mass analysis.  The fragmentation studies presented could 
be of significant  use for future identification of others 
monensin metabolites and showed that LC-ESI-MS/MS is 
a powerful tool to study the in vitro metabolism of drugs, 
allowing the identification and structural elucidation of 
novel metabolites.
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